Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HS1 loss drives cytoskeletal dysregulation and reduces sensitivity to BTK inhibition in chronic lymphocytic leukemia.

Journal of leukocyte biology·2026
Same author

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026
Same author

Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting.

Journal of geriatric oncology·2026
Same author

EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation.

HemaSphere·2026
Same author

Minimal residual disease in CLL: when does it really matter?

Blood·2026
Same author

Integrated multiomic profiling reveals 2 distinct splenic marginal zone lymphoma subgroups with prognostic relevance.

Blood advances·2026

Related Experiment Video

Updated: Nov 23, 2025

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.4K

Modeling the Leukemia Microenviroment In Vitro.

Cristina Scielzo1, Paolo Ghia2,3,4

  • 1Unit of Malignant B Cell Biology and 3D Modeling, Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milano, Italy.

Frontiers in Oncology
|January 4, 2021
PubMed
Summary

The tumor microenvironment significantly impacts B cell malignancies, promoting leukemia cell growth and drug resistance. Innovative 3D in vitro models are crucial for understanding these interactions and identifying new therapeutic targets.

Keywords:
3D models (three dimensional)B cell malignancieschronic lymphocytic leukemia (CLL)in vitromicroenvironment

More Related Videos

Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis
11:50

Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis

Published on: April 10, 2012

15.8K
Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

5.1K

Related Experiment Videos

Last Updated: Nov 23, 2025

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.4K
Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis
11:50

Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis

Published on: April 10, 2012

15.8K
Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

5.1K

Area of Science:

  • Hematology
  • Oncology
  • Cell Biology

Background:

  • The tumor microenvironment plays a critical role in B cell malignancies, influencing pathogenesis, development, and drug resistance.
  • Current in vitro models for hematological cancers are often simplified, limiting their ability to fully replicate in vivo conditions.

Purpose of the Study:

  • To review cellular and molecular interactions between B lymphocytes and their microenvironment.
  • To discuss innovative in vitro models for studying chronic lymphocytic leukemia (CLL).
  • To propose improvements for future in vitro models based on microenvironmental signaling.

Main Methods:

  • Literature review of cellular and molecular interactions in B cell malignancies.
  • Analysis of existing and novel in vitro models for hematological cancers, particularly CLL.
  • Discussion of key molecules and signals within the tumor microenvironment.

Main Results:

  • Established role of the microenvironment in promoting leukemic cell proliferation and drug resistance.
  • Limited complexity of current in vitro models for hematological cancers.
  • Need for more sophisticated models to study microenvironment-cancer cell crosstalk.

Conclusions:

  • Future in vitro models should incorporate higher cellular and molecular complexity, such as 3D culture systems.
  • Advanced 3D models can better replicate microenvironmental signaling and improve understanding of leukemia cell dissemination and homing.
  • Improved models will facilitate the identification of novel therapeutic targets for B cell malignancies.